• Explore /
  • Poster
  • / Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

Abstract Poster

Authors

null

Luis A. Diaz Jr.

Memorial Sloan Kettering Cancer Center, New York, NY

Luis A. Diaz Jr., Dung T. Le , Takayuki Yoshino , Thierry Andre , Johanna C. Bendell , Minori Koshiji , Yinghua Zhang , S. Peter Kang , Bao Lam , Dirk Jaeger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02563002

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS3618)

DOI

10.1200/JCO.2017.35.15_suppl.TPS3618

Abstract #

TPS3618

Poster Bd #

241a

Abstract Disclosures

Similar Posters

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.